Clinical Trial Update: A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique. [Phase 2]

View source ↗

Summary

Phase 2 trial of GlaxoSmithKline's RTS,S/AS02A malaria vaccine in children aged 1 to 4 years in Mozambique completed. The study assessed safety, immunogenicity …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• RTS,S/AS02A (RTS,S malaria vaccine with AS02A adjuvant)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Malaria | Phase 2 | Status: COMPLETED